SH3-SPOT: An algorithm to predict preferred ligands to different members of the SH3 gene family

被引:71
作者
Brannetti, B [1 ]
Via, A [1 ]
Cestra, G [1 ]
Cesareni, G [1 ]
Citterich, MH [1 ]
机构
[1] Univ Roma Tor Vergata, Dept Biol, Ctr Bioinformat Mol, I-00133 Rome, Italy
关键词
SH3; domain; prediction; specificity; protein/peptide interaction; bioinformatics;
D O I
10.1006/jmbi.2000.3670
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have developed a procedure to predict the peptide binding specificity of an SH3 domain from its sequence. The procedure utilizes information extracted from position-specific contacts derived from six SH3/peptide or SH3/protein complexes of known structure. The framework of SH3/peptide contacts defined on the structure of the complexes is used to build a residue-residue interaction database derived from ligands obtained by panning peptide libraries displayed on filamentous phage. The SH3-specific interaction database is a multidimensional array containing frequencies of position-specific contacts. As input, SH3-SPOT requires the sequence of an SH3 domain and of a query decapeptide ligand. The array, that we call the SH3-specific matrix, is then used to evaluate the probability that the peptide would bind the given SH3 domain. This procedure is fast enough to be applied to the entire protein sequence database. Panning experiments were performed to search putative specific ligands of different SH3 domains in a database of decapeptides, or in a database of protein sequences. The procedure ranked some of the natural partners of interaction of a number of SH3 domains among the best ligands of the similar to 5.6 x 10(9) different decapeptides in the SWISSPROT database. We expect the predictive power of the method to increase with the enrichment of the SH3-specific matrix by interaction data derived from new complex structures or from the characterization of new ligands. The procedure was developed using the SH3 domain family as test case but its application can easily be extended to other families of protein domains (such as, SH2, MHC, EH, PDZ, etc.). (C) 2000 Academic Press.
引用
收藏
页码:313 / 328
页数:16
相关论文
共 36 条
[11]   The proto-oncogene p120Cbl is a downstream substrate of the Hck protein-tyrosine kinase [J].
Howlett, CJ ;
Bisson, SA ;
Resek, ME ;
Tigley, AW ;
Robbins, SM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 257 (01) :129-138
[12]   Fyn associates with Cbl and phosphorylates tyrosine 731 in Cbl, a binding site for phosphatidylinositol 3-kinase [J].
Hunter, S ;
Burton, EA ;
Wu, SC ;
Anderson, SM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (04) :2097-2106
[13]   Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain [J].
Lee, CH ;
Saksela, K ;
Mirza, UA ;
Chait, BT ;
Kuriyan, J .
CELL, 1996, 85 (06) :931-942
[14]   STRUCTURAL DETERMINANTS OF PEPTIDE-BINDING ORIENTATION AND OF SEQUENCE SPECIFICITY IN SH3 DOMAINS [J].
LIM, WA ;
RICHARDS, FM ;
FOX, RO .
NATURE, 1994, 372 (6504) :375-379
[15]   A novel peptide-SH3 interaction [J].
Mongiovi, AM ;
Romano, PR ;
Panni, S ;
Mendoza, M ;
Wong, WT ;
Musacchio, A ;
Cesareni, G ;
Di Fiore, PP .
EMBO JOURNAL, 1999, 18 (19) :5300-5309
[16]   STRUCTURE AND FUNCTION OF THE SH3 DOMAIN [J].
MUSACCHIO, A ;
WILMANNS, M ;
SARASTE, M .
PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY, 1994, 61 (03) :283-297
[17]   HIGH-RESOLUTION CRYSTAL-STRUCTURES OF TYROSINE KINASE SH3 DOMAINS COMPLEXED WITH PROLINE-RICH PEPTIDES [J].
MUSACCHIO, A ;
SARASTE, M ;
WILMANNS, M .
NATURE STRUCTURAL BIOLOGY, 1994, 1 (08) :546-551
[18]   CRYSTAL-STRUCTURE OF A SRC-HOMOLOGY-3 (SH3) DOMAIN [J].
MUSACCHIO, A ;
NOBLE, M ;
PAUPTIT, R ;
WIERENGA, R ;
SARASTE, M .
NATURE, 1992, 359 (6398) :851-855
[19]   CHARACTERIZATION OF 2 85KD PROTEINS THAT ASSOCIATE WITH RECEPTOR TYROSINE KINASES, MIDDLE-T/PP60C-SRC COMPLEXES, AND PI3-KINASE [J].
OTSU, M ;
HILES, I ;
GOUT, I ;
FRY, MJ ;
RUIZLARREA, F ;
PANAYOTOU, G ;
THOMPSON, A ;
DHAND, R ;
HSUAN, J ;
TOTTY, N ;
SMITH, AD ;
MORGAN, SJ ;
COURTNEIDGE, SA ;
PARKER, PJ ;
WATERFIELD, MD .
CELL, 1991, 65 (01) :91-104
[20]  
Park RK, 1998, J IMMUNOL, V160, P5018